226 related articles for article (PubMed ID: 16176940)
1. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes.
Timmis AD; Chaitman BR; Crager M
Eur Heart J; 2006 Jan; 27(1):42-8. PubMed ID: 16176940
[TBL] [Abstract][Full Text] [Related]
2. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina).
Kosiborod M; Arnold SV; Spertus JA; McGuire DK; Li Y; Yue P; Ben-Yehuda O; Katz A; Jones PG; Olmsted A; Belardinelli L; Chaitman BR
J Am Coll Cardiol; 2013 May; 61(20):2038-45. PubMed ID: 23500237
[TBL] [Abstract][Full Text] [Related]
4. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
Stone PH; Gratsiansky NA; Blokhin A; Huang IZ; Meng L;
J Am Coll Cardiol; 2006 Aug; 48(3):566-75. PubMed ID: 16875985
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials.
Chaitman BR
J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S47-64. PubMed ID: 15378131
[TBL] [Abstract][Full Text] [Related]
6. Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials.
Wenger NK; Chaitman B; Vetrovec GW
Am J Cardiol; 2007 Jan; 99(1):11-8. PubMed ID: 17196454
[TBL] [Abstract][Full Text] [Related]
7. [Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. Results of CARISA].
Gratsianskiĭ NA
Kardiologiia; 2004; 44(3):78. PubMed ID: 15489836
[No Abstract] [Full Text] [Related]
8. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group.
Thadani U; Ezekowitz M; Fenney L; Chiang YK
Circulation; 1994 Aug; 90(2):726-34. PubMed ID: 8044941
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris.
Rousseau MF; Pouleur H; Cocco G; Wolff AA
Am J Cardiol; 2005 Feb; 95(3):311-6. PubMed ID: 15670536
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
Wilson SR; Scirica BM; Braunwald E; Murphy SA; Karwatowska-Prokopczuk E; Buros JL; Chaitman BR; Morrow DA
J Am Coll Cardiol; 2009 Apr; 53(17):1510-6. PubMed ID: 19389561
[TBL] [Abstract][Full Text] [Related]
11. Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine In Stable Angina (CARISA) randomized trial.
Sendón JL; Lee S; Cheng ML; Ben-Yehuda O;
Eur J Prev Cardiol; 2012 Oct; 19(5):952-9. PubMed ID: 22689417
[TBL] [Abstract][Full Text] [Related]
12. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.
Chaitman BR; Skettino SL; Parker JO; Hanley P; Meluzin J; Kuch J; Pepine CJ; Wang W; Nelson JJ; Hebert DA; Wolff AA;
J Am Coll Cardiol; 2004 Apr; 43(8):1375-82. PubMed ID: 15093870
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial.
Morrow DA; Scirica BM; Chaitman BR; McGuire DK; Murphy SA; Karwatowska-Prokopczuk E; McCabe CH; Braunwald E;
Circulation; 2009 Apr; 119(15):2032-9. PubMed ID: 19349325
[TBL] [Abstract][Full Text] [Related]
14. Ranolazine in the management of chronic stable angina.
Zerumsky K; McBride BF
Am J Health Syst Pharm; 2006 Dec; 63(23):2331-8. PubMed ID: 17106005
[TBL] [Abstract][Full Text] [Related]
15. Ranolazine (Ranexa) for chronic stable angina.
Ndegwa S
Issues Emerg Health Technol; 2007 Jun; (99):1-6. PubMed ID: 17595750
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c.
Arnold SV; McGuire DK; Spertus JA; Li Y; Yue P; Ben-Yehuda O; Belardinelli L; Jones PG; Olmsted A; Chaitman BR; Kosiborod M
Am Heart J; 2014 Oct; 168(4):457-465.e2. PubMed ID: 25262254
[TBL] [Abstract][Full Text] [Related]
17. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group.
Pepine CJ; Wolff AA
Am J Cardiol; 1999 Jul; 84(1):46-50. PubMed ID: 10404850
[TBL] [Abstract][Full Text] [Related]
18. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem.
Cocco G; Rousseau MF; Bouvy T; Cheron P; Williams G; Detry JM; Pouleur H
J Cardiovasc Pharmacol; 1992 Jul; 20(1):131-8. PubMed ID: 1383622
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).
Koren MJ; Crager MR; Sweeney M
J Am Coll Cardiol; 2007 Mar; 49(10):1027-34. PubMed ID: 17349881
[TBL] [Abstract][Full Text] [Related]
20. Spotlight on ranolazine in chronic stable angina pectoris.
Siddiqui MA; Keam SJ
Am J Cardiovasc Drugs; 2006; 6(5):357-9. PubMed ID: 17083271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
